Enlivex Therapeutics Ltd (ENLV) — Capital Reinvestment Ratio

Latest as of March 2020: 0.05x

Enlivex Therapeutics Ltd (ENLV) has a Capital Reinvestment Ratio of 0.05x as of March 2020, meaning it reinvests 0% of its operating cash flow (ILA779.00K) in capital expenditures (ILA39.00K). See ENLV equity to assets ratio to measure how much of total assets are equity-financed.

Capital Reinvestment Ratio

0.05x

Capex / Operating Cash Flow

Operating Cash Flow

ILA779.00K

ILA

Capital Expenditures

ILA39.00K

ILA

Data as of

Mar 2020

Most recent filing

Annual Capital Reinvestment Ratio for Enlivex Therapeutics Ltd (None–None)

Year-by-year Capital Reinvestment Ratio for Enlivex Therapeutics Ltd from None to None. For live market cap and broader valuation context, see Enlivex Therapeutics Ltd (ENLV) total market value.

Year	Reinvestment Ratio	Operating CF (ILA)	Capital Expenditures	YoY Change

Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow